Latest Innovus Pharmaceuticals Inc (INNV) Headlines
Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017
M2 - Wed Feb 26, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjj4j7/personal_accident) has announced the addition of the "Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017" report to their offering. The Greek personal accident and health insurance segment accounted for the lowest share of premiums in the overall insurance industry in 2012. Demand for healthcare services and private health insurance increased during the review period (2008-2012), due to the inadequate service provided by public healthcare institutions and increasing per capita healthcare expenditure. Travel insurance accounted for the largest share of the segment. Growth in the category was supported by the introduction of low-cost airlines which increased the number of outbound tourists. Over the forecast period (2012-2017), the growth of the personal accident and health segment is expected to be driven by the travel and health insurance categories. Overall, the value of the Greek personal accident and health segment is expected to increase at a forecast-period compound annual growth rate (CAGR) of 5.5%. Key Topics Covered 1 Executive Summary 2 Introduction 3 Greek Insurance Industry Attractiveness 4 Personal Accident and Health Insurance Segment Outlook 5 Analysis by Distribution Channels 6 Porter's Five Forces Analysis - Greek Personal Accident and Health Insurance 7 Reinsurance Growth Dynamics and Challenges 8 Governance, Risk and Compliance 9 Competitive Landscape and Strategic Insights 10 Business Environment and Country Risk 11 Appendix Companies Mentioned - Eurolife - ING Greek Life Insurance - Metlife Alico For more information visit http://www.researchandmarkets.com/research/bj...l_accident About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Innovus Pharma reports market launch of EjectDelay in the US
M2 - Mon Feb 24, 7:02AM CST
Pharmaceuticals company Innovus Pharmaceuticals (Other OTC:INNV) disclosed on Friday the market availability of its over the counter (OTC) benzocaine-based topical premature ejaculation treatment, EjectDelay, in the US.
Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States
GlobeNewswire - Fri Feb 21, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced the availability of its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in the United States ("U.S.").
Innovus Pharma to Exhibit Zestra(R) its Clinically Proven Product for Female Sexual Arousal and Desire at the International Society for the Study of Women's Sexual Health 2014 Annual Meeting in San Diego
GlobeNewswire - Thu Feb 20, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTC BB:INNV) today announced that it will exhibit Zestra(R), its topical over the counter ("OTC") product for female sexual arousal and desire at the 2014 Annual International Society for the Study of Women's Sexual Health Meeting in San Diego from February 20-22, 2014.
Innovus Pharmaceuticals Inc elects Lynnette Dillen as CFO & EVP
M2 - Wed Feb 12, 4:23AM CST
Sexual dysfunction products company Innovus Pharmaceuticals Inc (Other OTC:INNV) revealed on Tuesday the appointment of Lynnette Dillen as executive vice president and chief financial officer for its finance, accounting, human resources, information technology and investor relations.
Innovus Pharma Expands Management Team and Adds Chief Financial Officer
GlobeNewswire - Tue Feb 11, 5:15AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV), today announced that Lynnette Dillen has joined the company as Executive Vice President and Chief Financial Officer with responsibility for finance, accounting, human resources, information technology and investor relations.
Innovus Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference in New York
GlobeNewswire - Wed Feb 05, 5:00AM CST
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., Chief Executive Officer and President, will present at the 16th Annual BIO CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York February 10-11, 2014. Dr. Damaj is scheduled to present on Monday, February 10th at 11:00 a.m. EST in the Conrad Room. Dr. Damaj will give an overview of the Company and discuss the recent acquisition of Semprae Laboratories, Inc., the Company's growing pipeline and its projected growth. In addition, he will preview the recent accomplishments of the Company and the upcoming milestones.
TRENDnet(R) 720p Cloud Cameras Now Available
Marketwire - Tue Feb 04, 6:44AM CST
TRENDnet, a best-in-class wired and wireless networking hardware brand, today announces the availability of the HD Wireless Day / Night Cloud Camera (model TV-IP762IC) and HD Wireless Day / Night PTZ Cloud Camera (model TV-IP862IC).
Ogun APC - the Trouble That Was Foretold
by Daud Olatunji - All Africa Global Media - Wed Jan 22, 2:09AM CST
The emergence of Senator Ibikunle Amosun as the gubernatorial flag bearer of the defunct Action Congress of Nigeria, ACN in 2011 predicted trouble for the status quo. It didn't take long for it to burst.
Innovus Pharma Provides Regulatory and Commercial Update on the Label Indication for Zestra(R) for Female Sexual Desire Disorder ("FSDD") from Health Canada
GlobeNewswire - Fri Jan 10, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that its newly acquired wholly-owned subsidiary, Semprae Laboratories, Inc. ("Semprae") is working with Health Canada to finalize the packaging for the indication for its topical over the counter ("OTC") Natural Health Product, Zestra(R), for the temporary improved sexual desire in women suffering from female sexual desire disorder" ("FSDD"). The first Canadian Product License approval for this indication was obtained by Semprae in July 2012, but never applied to the Zestra(R) label. The Company is expected to finalize the new packaging for this product with Health Canada with the approved FSDD indication within 90 days. In addition, the Company is filing to expand the indication to women with Female Sexual Arousal Disorder (FSAD) due to statistically significant improvement in arousal and Female Sexual Function Index (FSFI) scores observed in its large clinical trial in women with FSAD.
Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.
GlobeNewswire - Mon Dec 30, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company acquired Semprae Laboratories, Inc. ("Semprae") through a merger and for shares of common stock of Innovus Pharma. Semprae is a New Jersey company founded by women in 2008 with the goal of improving women's sexual lives. From the beginning, Semprae has been marketing Zestra(TM), the first non-prescription product clinically proven to increase arousal, sensation, pleasure and satisfaction in women. In 2011, Semprae introduced Zestra Glide(TM), an accompanying water based lubricant. Together the two products had gross sales of approximately $1 million in 2013.
Innovus Pharma Announces Start of Its CIRCUMserum(TM) Commercial Phase in Morocco With Initial Order of 10,000 Units by Its Partner Ovation Pharma
GlobeNewswire - Fri Dec 27, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) announced today that its topical treatment for reduced penile sensitivity, CIRCUMserum(TM), has received importation and commercialization approval from the Moroccan Ministry of Health. In addition, the Company announced that its partner Ovation Pharma SARL ("Ovation Pharma") placed its first order for 10,000 units of CIRCUMserum(TM) and provided the Company with a partial payment for the order. Innovus expects to deliver the units in Q1 2014 in time for Ovation Pharma's official launch of the product in Morocco at that time. The Company and Ovation Pharma entered into a license and distribution agreement (the "License Agreement") under which Innovus Pharma granted to Ovation Pharma an exclusive license to market and sell Innovus Pharma's CIRCUMserum(TM) in Morocco. Pursuant to the License Agreement, Ovation Pharma may pay Innovus Pharma up to approximately $11.25 million for the achievement of certain commercial milestones described therein.
Innovus Pharmaceuticals Inc wins Health Canada's approval for EjectDelay
M2 - Mon Dec 09, 4:40AM CST
Pharmaceuticals company Innovus Pharmaceuticals Inc (OTC Markets:INNV) stated on Friday that its product license for its over the counter (OTC) benzocaine-based topical premature ejaculation treatment EjectDelay has been approved in Canada.
Innovus Pharma Receives Product License Approval of EjectDelay(TM) for Premature Ejaculation From Health Canada
GlobeNewswire - Fri Dec 06, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company received the approval of its product license for its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in Canada.
Innovus Pharma Selects Lebanese-Canadian Hospital for Its Post-Marketing Clinical Trials for CIRCUMserum(TM) and EjectDelay(TM)
GlobeNewswire - Mon Nov 11, 5:30AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company selected the Lebanese-Canadian Hospital in Beirut, Lebanon for its two post-marketing trials for CIRCUMserum(TM) to alleviate reduced penile sensitivity and EjectDelay(TM) for premature ejaculation.
Innovus Pharmaceuticals to Present at the BIO Europe 2013 Conference in Vienna
GlobeNewswire - Thu Oct 31, 5:30AM CDT
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., President and Chief Executive Officer of the Company, will present at the BIO-Europe 2013 conference to be held in Vienna, Austria on November 4-6, 2013. Dr. Damaj is scheduled to present on Tuesday, November 5 at 10:00 a.m. local Vienna time.
Innovus Pharmaceuticals Inc submits Product License Application to commercialise OTC EjectDelay in Canada
M2 - Wed Oct 30, 7:13AM CDT
Pharmaceuticals company Innovus Pharmaceuticals Inc (Other OTC:INNV) said on Tuesday that it has submitted its Product License Application with Health Canada to market its premature ejaculation topical treatment, EjectDelay.
Innovus Pharma Files Its Product License Application for Commercialization of CIRCUMserum(TM) as a Natural Health Product for Alleviation of Reduced Penile Sensitivity in Canada
GlobeNewswire - Wed Oct 30, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company filed its Product License Application with Health Canada as a Natural Health Product (NPN) to market its reduced penile sensitivity topical treatment CIRCUMserum with the indication to alleviate reduced penile sensitivity. CIRCUMserum has the active medicinal ingredient cinnamon oil (cinnamaldehyde) 0.75% and works by activating the transient receptor potential channel A1 (TRPA1) channels leading to exciting the nociceptive responsive nerve endings to increase penile sensitivity without affecting the thickness of the skin. If accepted by Health Canada, CIRCUMserum will be available over-the-counter as a 0.75% strength in 10mL metered dose dispenser and will not require a prescription. The product is not reimbursed by the Canadian government, therefore, the Company will be able to set the retail price through its potential commercial partners.
Innovus Pharma Files Its Product License Application for Commercialization of EjectDelay(TM) for Premature Ejaculation in Canada
GlobeNewswire - Tue Oct 29, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV), today announced that the Company filed its Product License Application with Health Canada to market its premature ejaculation topical treatment EjectDelay. EjectDelay has the active drug Benzocaine and works by blocking the sodium channels of the nerves and therefore temporarily desensitizing the glans of the penis allowing longer ejaculatory time. If accepted by Health Canada, EjectDelay will be available as a 7.5% strength in 2oz over-the-counter gel and will not require a prescription. The product is not expected to be reimbursed by the Canadian government, therefore, the Company will be able to set the retail price through its potential commercial partners.
Innovus Pharma Expands Management Team and Adds Acting General Counsel and Vice President of Finance
GlobeNewswire - Thu Sep 19, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) today announced that Randy Berholtz was appointed as Acting General Counsel of the Company, an expansion to his previously appointed position as Secretary, and Lynnette Dillen has joined the Company as Vice President of Finance. Ms. Dillen will be responsible for administrative, financial, and risk management of the company.
Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017
M2 - Wed Feb 26, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjj4j7/personal_accident) has announced the addition of the "Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017" report to their offering. The Greek personal accident and health insurance segment accounted for the lowest share of premiums in the overall insurance industry in 2012. Demand for healthcare services and private health insurance increased during the review period (2008-2012), due to the inadequate service provided by public healthcare institutions and increasing per capita healthcare expenditure. Travel insurance accounted for the largest share of the segment. Growth in the category was supported by the introduction of low-cost airlines which increased the number of outbound tourists. Over the forecast period (2012-2017), the growth of the personal accident and health segment is expected to be driven by the travel and health insurance categories. Overall, the value of the Greek personal accident and health segment is expected to increase at a forecast-period compound annual growth rate (CAGR) of 5.5%. Key Topics Covered 1 Executive Summary 2 Introduction 3 Greek Insurance Industry Attractiveness 4 Personal Accident and Health Insurance Segment Outlook 5 Analysis by Distribution Channels 6 Porter's Five Forces Analysis - Greek Personal Accident and Health Insurance 7 Reinsurance Growth Dynamics and Challenges 8 Governance, Risk and Compliance 9 Competitive Landscape and Strategic Insights 10 Business Environment and Country Risk 11 Appendix Companies Mentioned - Eurolife - ING Greek Life Insurance - Metlife Alico For more information visit http://www.researchandmarkets.com/research/bj...l_accident About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Innovus Pharma reports market launch of EjectDelay in the US
M2 - Mon Feb 24, 7:02AM CST
Pharmaceuticals company Innovus Pharmaceuticals (Other OTC:INNV) disclosed on Friday the market availability of its over the counter (OTC) benzocaine-based topical premature ejaculation treatment, EjectDelay, in the US.
Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States
GlobeNewswire - Fri Feb 21, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced the availability of its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in the United States ("U.S.").
Innovus Pharma to Exhibit Zestra(R) its Clinically Proven Product for Female Sexual Arousal and Desire at the International Society for the Study of Women's Sexual Health 2014 Annual Meeting in San Diego
GlobeNewswire - Thu Feb 20, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTC BB:INNV) today announced that it will exhibit Zestra(R), its topical over the counter ("OTC") product for female sexual arousal and desire at the 2014 Annual International Society for the Study of Women's Sexual Health Meeting in San Diego from February 20-22, 2014.
Innovus Pharmaceuticals Inc elects Lynnette Dillen as CFO & EVP
M2 - Wed Feb 12, 4:23AM CST
Sexual dysfunction products company Innovus Pharmaceuticals Inc (Other OTC:INNV) revealed on Tuesday the appointment of Lynnette Dillen as executive vice president and chief financial officer for its finance, accounting, human resources, information technology and investor relations.
Innovus Pharma Expands Management Team and Adds Chief Financial Officer
GlobeNewswire - Tue Feb 11, 5:15AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV), today announced that Lynnette Dillen has joined the company as Executive Vice President and Chief Financial Officer with responsibility for finance, accounting, human resources, information technology and investor relations.
Innovus Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference in New York
GlobeNewswire - Wed Feb 05, 5:00AM CST
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., Chief Executive Officer and President, will present at the 16th Annual BIO CEO & Investor Conference, to be held at the Waldorf-Astoria Hotel in New York February 10-11, 2014. Dr. Damaj is scheduled to present on Monday, February 10th at 11:00 a.m. EST in the Conrad Room. Dr. Damaj will give an overview of the Company and discuss the recent acquisition of Semprae Laboratories, Inc., the Company's growing pipeline and its projected growth. In addition, he will preview the recent accomplishments of the Company and the upcoming milestones.
TRENDnet(R) 720p Cloud Cameras Now Available
Marketwire - Tue Feb 04, 6:44AM CST
TRENDnet, a best-in-class wired and wireless networking hardware brand, today announces the availability of the HD Wireless Day / Night Cloud Camera (model TV-IP762IC) and HD Wireless Day / Night PTZ Cloud Camera (model TV-IP862IC).
Ogun APC - the Trouble That Was Foretold
by Daud Olatunji - All Africa Global Media - Wed Jan 22, 2:09AM CST
The emergence of Senator Ibikunle Amosun as the gubernatorial flag bearer of the defunct Action Congress of Nigeria, ACN in 2011 predicted trouble for the status quo. It didn't take long for it to burst.
Innovus Pharma Provides Regulatory and Commercial Update on the Label Indication for Zestra(R) for Female Sexual Desire Disorder ("FSDD") from Health Canada
GlobeNewswire - Fri Jan 10, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that its newly acquired wholly-owned subsidiary, Semprae Laboratories, Inc. ("Semprae") is working with Health Canada to finalize the packaging for the indication for its topical over the counter ("OTC") Natural Health Product, Zestra(R), for the temporary improved sexual desire in women suffering from female sexual desire disorder" ("FSDD"). The first Canadian Product License approval for this indication was obtained by Semprae in July 2012, but never applied to the Zestra(R) label. The Company is expected to finalize the new packaging for this product with Health Canada with the approved FSDD indication within 90 days. In addition, the Company is filing to expand the indication to women with Female Sexual Arousal Disorder (FSAD) due to statistically significant improvement in arousal and Female Sexual Function Index (FSFI) scores observed in its large clinical trial in women with FSAD.
Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.
GlobeNewswire - Mon Dec 30, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company acquired Semprae Laboratories, Inc. ("Semprae") through a merger and for shares of common stock of Innovus Pharma. Semprae is a New Jersey company founded by women in 2008 with the goal of improving women's sexual lives. From the beginning, Semprae has been marketing Zestra(TM), the first non-prescription product clinically proven to increase arousal, sensation, pleasure and satisfaction in women. In 2011, Semprae introduced Zestra Glide(TM), an accompanying water based lubricant. Together the two products had gross sales of approximately $1 million in 2013.
Innovus Pharma Announces Start of Its CIRCUMserum(TM) Commercial Phase in Morocco With Initial Order of 10,000 Units by Its Partner Ovation Pharma
GlobeNewswire - Fri Dec 27, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) announced today that its topical treatment for reduced penile sensitivity, CIRCUMserum(TM), has received importation and commercialization approval from the Moroccan Ministry of Health. In addition, the Company announced that its partner Ovation Pharma SARL ("Ovation Pharma") placed its first order for 10,000 units of CIRCUMserum(TM) and provided the Company with a partial payment for the order. Innovus expects to deliver the units in Q1 2014 in time for Ovation Pharma's official launch of the product in Morocco at that time. The Company and Ovation Pharma entered into a license and distribution agreement (the "License Agreement") under which Innovus Pharma granted to Ovation Pharma an exclusive license to market and sell Innovus Pharma's CIRCUMserum(TM) in Morocco. Pursuant to the License Agreement, Ovation Pharma may pay Innovus Pharma up to approximately $11.25 million for the achievement of certain commercial milestones described therein.
Innovus Pharmaceuticals Inc wins Health Canada's approval for EjectDelay
M2 - Mon Dec 09, 4:40AM CST
Pharmaceuticals company Innovus Pharmaceuticals Inc (OTC Markets:INNV) stated on Friday that its product license for its over the counter (OTC) benzocaine-based topical premature ejaculation treatment EjectDelay has been approved in Canada.
Innovus Pharma Receives Product License Approval of EjectDelay(TM) for Premature Ejaculation From Health Canada
GlobeNewswire - Fri Dec 06, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company received the approval of its product license for its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in Canada.
Innovus Pharma Selects Lebanese-Canadian Hospital for Its Post-Marketing Clinical Trials for CIRCUMserum(TM) and EjectDelay(TM)
GlobeNewswire - Mon Nov 11, 5:30AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company selected the Lebanese-Canadian Hospital in Beirut, Lebanon for its two post-marketing trials for CIRCUMserum(TM) to alleviate reduced penile sensitivity and EjectDelay(TM) for premature ejaculation.
Innovus Pharmaceuticals to Present at the BIO Europe 2013 Conference in Vienna
GlobeNewswire - Thu Oct 31, 5:30AM CDT
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"), www.innovuspharma.com, (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., President and Chief Executive Officer of the Company, will present at the BIO-Europe 2013 conference to be held in Vienna, Austria on November 4-6, 2013. Dr. Damaj is scheduled to present on Tuesday, November 5 at 10:00 a.m. local Vienna time.
Innovus Pharmaceuticals Inc submits Product License Application to commercialise OTC EjectDelay in Canada
M2 - Wed Oct 30, 7:13AM CDT
Pharmaceuticals company Innovus Pharmaceuticals Inc (Other OTC:INNV) said on Tuesday that it has submitted its Product License Application with Health Canada to market its premature ejaculation topical treatment, EjectDelay.
Innovus Pharma Files Its Product License Application for Commercialization of CIRCUMserum(TM) as a Natural Health Product for Alleviation of Reduced Penile Sensitivity in Canada
GlobeNewswire - Wed Oct 30, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company filed its Product License Application with Health Canada as a Natural Health Product (NPN) to market its reduced penile sensitivity topical treatment CIRCUMserum with the indication to alleviate reduced penile sensitivity. CIRCUMserum has the active medicinal ingredient cinnamon oil (cinnamaldehyde) 0.75% and works by activating the transient receptor potential channel A1 (TRPA1) channels leading to exciting the nociceptive responsive nerve endings to increase penile sensitivity without affecting the thickness of the skin. If accepted by Health Canada, CIRCUMserum will be available over-the-counter as a 0.75% strength in 10mL metered dose dispenser and will not require a prescription. The product is not reimbursed by the Canadian government, therefore, the Company will be able to set the retail price through its potential commercial partners.
Innovus Pharma Files Its Product License Application for Commercialization of EjectDelay(TM) for Premature Ejaculation in Canada
GlobeNewswire - Tue Oct 29, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV), today announced that the Company filed its Product License Application with Health Canada to market its premature ejaculation topical treatment EjectDelay. EjectDelay has the active drug Benzocaine and works by blocking the sodium channels of the nerves and therefore temporarily desensitizing the glans of the penis allowing longer ejaculatory time. If accepted by Health Canada, EjectDelay will be available as a 7.5% strength in 2oz over-the-counter gel and will not require a prescription. The product is not expected to be reimbursed by the Canadian government, therefore, the Company will be able to set the retail price through its potential commercial partners.
Innovus Pharma Expands Management Team and Adds Acting General Counsel and Vice President of Finance
GlobeNewswire - Thu Sep 19, 5:30AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) today announced that Randy Berholtz was appointed as Acting General Counsel of the Company, an expansion to his previously appointed position as Secretary, and Lynnette Dillen has joined the Company as Vice President of Finance. Ms. Dillen will be responsible for administrative, financial, and risk management of the company.
